Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Authors:
  • F(For the German Dermatologic Cooperative Oncology Group (DeCOG)
    For the German Dermatologic Cooperative Oncology Group (DeCOG)

Abstract
Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only been evaluated in a selected number of patients.

This publication has 19 references indexed in Scilit: